 | | Vol. 11.35 – 15 September, 2020 |
| |
|
|
| Targeting IL-20 not only prolonged survival and attenuated PD-L1 expression in both murine models but also inhibited tumor growth and mitigated M2-like polarization in the orthotopic pancreatic ductal adenocarcinoma model.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | | In CD8+ splenic T cells from the high fat-high sucrose chow fed mice, glycolysis/basal respiration ratio was significantly reduced and reversed by metformin.
[Scientific Reports] |
| |
|
|
| Using a reporter gene, scientists identified metaplastic cells that originated from acinar cells and expressed two transcription factors, Onecut2 and Foxq1. Further analyses of metaplastic acinar cell heterogeneity defined six acinar metaplastic cell types and states, including stomach-specific cell types.
[Nature Communications] |
|
|
|
| The authors clarified the unique consequences of YAP/TAZ activation in the ductal cell population of the pancreas by generating mice with pancreatic duct cell-specific, inducible knockouts of Lats1 and Lats2, the main kinases upstream of YAP/TAZ.
[Cancer Research] |
|
|
|
| Scientists characterized the mechanistic and functional implications of the histone methyltransferase Enhancer of Zeste Homologue 2 (EZH2) in controlling pancreatic ductal adenocarcinoma plasticity, dedifferentiation, and molecular subtype identity.
[Cancer Research] |
|
|
|
| LC‐MS/MS proteomic analysis revealed that cancer‐associated fibroblasts (CAFs) that overexpressed hMENAΔv6 secreted the AXL ligand GAS6, favoring the invasiveness of AXL‐expressing pancreatic ductal adenocarcinoma and non‐small cell lung cancer cells.
[EMBO Reports] |
|
|
|
| Researchers demonstrated that tripartite motif-containing 2 (TRIM2) was expressed in a high percentage of pancreatic tumors. High TRIM2 expression was negatively correlated with the outcome of pancreatic cancer. TRIM2 silencing significantly inhibited the proliferation, migration, invasion, and in vivo tumorigenicity of pancreatic cancer cells.
[Oncogene] |
|
|
|
| Investigators elucidated the role of hu-antigen R (HuR) played in pancreatic cancer cell epithelial to mesenchymal transition, and developed a novel inhibitor specifically interrupting HuR-RNA binding.
[Molecular Cancer therapeutics] |
|
|
|
| Scientists used an in vitro pancreatic ductal adenocarcinoma model of SMAD4 positive and negative cells to investigate the interplay between circadian rhythms, the TGFβ canonical signaling pathway and its impact on tumor malignancy.
[iScience] |
|
|
|
|
| This review discusses the various scaffold platforms and design parameters that have been identified for the manufacture of hPSC-derived β-cells, and the transplantation of islets/β-cells to maintain normal blood glucose levels
[Endocrinology] |
|
|
|
| Cells in different tissues, including endocrine cells in the pancreas, live in complex microenvironments that are rich in cellular and acellular components. Investigators review current research on the interplay between the islet cellular and acellular components, and the role these components play in beta cell physiology and pathophysiology. Although beta cell failure is a key pathomechanism in diabetes, its causes are far from being fully elucidated.
[Diabetologia] |
|
|
|
| The authors discuss the use of dipeptidyl peptidase 4 inhibitors (DPP4i) in the treatment of type 2 diabetes mellitus, highlighting their benefits and risks. They focus primarily on the five DPP4i with the widest geographical distribution.
[Nature Reviews Endocrinology] |
|
|
|
|
| Adocia announced positive preliminary results from the extension part of the Phase Ib study of M1Pram, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a mealtime insulin with a similar time-action profile to human insulin and the main circulating metabolite of insulin glargine.
[Adocia] |
|
|
|
| Erytech Pharma has announced the hosting of a Key Opinion Leader (KOL) event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting. TRYbeCA-1, the pivotal Phase III clinical trial evaluating Erytech’s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has randomized more than 450 of the approximately 500 patients to be enrolled in the trial.
[Erytech Pharma Inc. (GlobeNewswire Inc.)] |
|
|
|
|
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Washington University in St. Louis – St. Louis, Missouri, United States |
|
|
|
| | Cold Spring Harbor Laboratory – New York, New York, United States |
|
|
|
| | Weill Cornell Medicine – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
